Oral or Injectable GLP-1: How We Choose a Route
Quick answer
Oral and injectable GLP-1 medicines differ in absorption, dosing, evidence, and practical considerations; neither route is automatically best for everyone. A prescriber should choose based on the specific product, medical history, preferences, and local approval, with instructions followed exactly.
Weight-management medicines now come as weekly injections and as daily tablets. Both act on GLP-1 signalling, and choosing between them is a practical clinical decision rather than a matter of one being better in the abstract.
Reasons to favour a weekly injection
- Once-weekly dosing suits people who dislike daily routines
- Dual GIP/GLP-1 action, available only by injection, produces the highest average weight reduction in trials
- Steadier drug levels can mean smoother tolerance for some patients
Reasons to favour a daily tablet
- Needle aversion is common and legitimate, and a medicine that is taken beats a medicine that is avoided
- No sharps, no refrigeration, easier travel
- A shorter-acting medicine can be stopped more quickly if side effects are troublesome
Factors that decide it in practice
Previous tolerance of GLP-1 medicines, current medicines and interactions, diabetes treatment and hypoglycaemia risk, pregnancy plans, gastrointestinal history including pancreatitis or gallbladder disease, work and travel patterns, and cost over the expected duration of treatment.
What stays identical
Dose escalation is gradual in both cases. Protein intake and resistance training protect muscle in both cases. Blood tests are reviewed before a plan is structured in both cases. Neither route is suitable in pregnancy, and neither should be sourced without a prescription and clinical assessment.
The useful question is not which medicine is strongest, but which treatment you can sustain safely for as long as it is clinically appropriate. That answer differs between patients, which is why it belongs in a consultation.
Reviewed by
Dr Chinnadorai Rajeswaran
Specialist Endocrinologist · MBBS MRCP FRCP
Last Reviewed: November 2026
Read about medication and related care.
Related insights
Weight Regain After GLP-1 Treatment: Why It Happens
Weight regain after stopping GLP-1 treatment is common because appetite and weight-regulating biology persist, though individual responses differ. Discuss a long-term plan with the prescriber before stopping or restarting, and do not alter doses independently.
Foundayo (Orforglipron): What a Daily Tablet Changes
Foundayo is a once-daily orforglipron tablet licensed in the UK, offering an oral route without the fasting routine required for oral semaglutide. Taking a tablet rather than an injection does not remove the need for a doctor to assess suitability, monitor side effects and review ongoing treatment.
Retatrutide: What the Research Shows So Far
Retatrutide remains investigational, with ongoing trials assessing its benefits, risks and longer-term safety. The evidence is not yet complete, and it is not licensed or available at our clinics; products sold online are not approved alternatives.